Top Markets
Coin of the day
IMBdx IMBdx

IMBdx

461030
Rangering i aksjer #27702
IMBdx, Inc. specializes in developing advanced liquid biopsy technologies for... IMBdx, Inc. specializes in developing advanced liquid biopsy technologies for cancer detection and management. The company's core mission revolves around three key areas: facilitating the diagnosis and treatment strategies for advanced-stage cancers, enabling the early identification of cancer recurrence after surgical interventions, and providing solutions for the early diagnosis of cancer. Its notable product offerings include AlphaLiquid, CancerDetect, and CancerFind. The firm was established by Tae-Yu Kim, Sung-Tae Moon, and Doo-Hee Bang on July 5, 2018, and maintains its headquarters in Seoul, South Korea.
Aksjekurs
$2.18
Markedsverdi
$31.27M
Endring (1 dag)
2.27%
Endring (1 år)
-61.30%
Land
KR
Handel IMBdx (461030)

Kategori

Utbytteavkastning for IMBdx (461030)
IMBdx (aksjesymbol: 461030) sin utbytteavkastning (TTM) per 2026 er: 0
Gjennomsnittlig utbytteavkastning de siste 5 årene: 0.00%
Utbytteavkastning for IMBdx (461030) fra 2026 til 2026
Utbytteavkastning ved slutten av hvert år (TTM)
År Utbytteavkastning Endre
Ikke nok data for de angitte datoene.
Utbytteavkastning (TTM) for lignende selskaper eller konkurrenter
Selskap Utbytteavkastning Land
0.00%
US
0.00%
US
0.00%
NL
3.12%
AU
0.00%
CH